NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

Geert R. D'Haens  1     Marla C. Dubinsky  2     Miguel Regueiro  3     Genoile O. Santana  4     Joana Torres  5     nicole kulisek  6     Sean Gardiner  7     Rajiv Mundayat  7     Jerome Paulissen  7     Nervin Lawendy  6     Chinyu Su  6     Irene Modesto  7     William Sandborn  8    
1 Amsterdam University Medical Centres, Amsterdam, Netherlands
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Cleveland Clinic, Cleveland, United States
4 University of the State of Bahia, Salvador, Brazil
5 Hospital Beatriz ├éngelo, Loures and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
6 Pfizer Inc, Collegeville, United States
7 Pfizer Inc, New York, United States
8 University of California San Diego, La Jolla, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing